Drug Trial Radar · NCT04140526
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
733
Planned (sponsor's estimate)
Start
Sep 16, 2020
Primary completion
Dec 31, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- OncoC4, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Oct 28, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.
Conditions
- Non Small Cell Lung Cancer
- Advanced Solid Tumor
- Metastatic Melanoma
- Metastatic Head and Neck Carcinoma
- Metastatic Renal Cell Carcinoma
- Metastatic Colorectal Cancer
- Sarcomas
- Metastatic Prostate Cancer
- Ovarian Cancer
- Small Cell Lung Cancer
- Metastatic Breast Cancer
- Pancreas Cancer
- Gastric Cancer
- Esophageal Cancer
- Gastroesophageal Junction Adenocarcinoma
- Cervical Cancer
- Adenoid Cystic Carcinoma
- Salivary Gland Cancer
- Urothelial Carcinoma
Interventions
ONC-392Drug
ONC-392 will be given by intravenous infusion, once every 21 days (Q3W). In Part C Arm M and in Part D, ONC-392 will be given Q4W.
PembrolizumabDrug
Pembrolizumab will be given intravenous (IV) infusion at 200 mg/cycle, once every 21 days (Q3W).
DocetaxelDrug
Docetaxel will be given intravenous (IV) infusion at 75 mg/m2, once every 21 days (Q3W).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT) in monotherapyTime frame: 21 days
- Maximal tolerable dose (MTD) in monotherapyTime frame: 21 days
- Recommended Phase II Dose (RP2D)Time frame: 21 days
- Rate of treatment related adverse events (TRAE) according to CTCAE v5.0Time frame: One year
Locations
37 sites in 2 countries. Site status is shown where the registry gives one.
Highlands Oncology Group
Springdale, Arkansas
University of California at Davis
Davis, California
The Oncology Institute of Hope and Innovation
Downey, California
City of Hope Cancer Center
Duarte, California
University of Colorado Hospital
Aurora, Colorado
Nuvance Health
Norwalk, Connecticut
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Florida Cancer Specialists
Atlantis, Florida
University of Florida Health Cancer Center
Gainesville, Florida
Ocala Oncology Florida Cancer Affiliates
Ocala, Florida
AdventHealth Cancer Institute
Orlando, Florida
Memorial Cancer Institute
Pembroke Pines, Florida
Emory University Winship Cancer Institute
Atlanta, Georgia
Norton Health
Lexington, Kentucky
Greater Baltimore Medical Center
Baltimore, Maryland
The Center for Cancer and Blood Disorders
Bethesda, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan Medical Center
Ann Arbor, Michigan
Atlantic Healthcare System
Morristown, New Jersey
Memorial Sloan Kettering Cancer Center
New York, New York
University of Cincinnati Medical Center
Cincinnati, Ohio
The Ohio State University James Cancer Center
Columbus, Ohio
Zangmeister Cancer Center
Columbus, Ohio
Pennsylvania Cancer Specialists & Research Institute (Formerly Gettysburg Cancer Center)
Gettysburg, Pennsylvania
Prisma Health
Greenville, South Carolina
Tennessee Oncology Chattanooga Memorial Plaza
Chattanooga, Tennessee
Tennessee Oncology - Nashville
Nashville, Tennessee
Houston Methodist Cancer Center
Houston, Texas
Oncology Consultants
Houston, Texas
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah
NEXT/Virginia Cancer Specialists
Fairfax, Virginia
University of Washington / Fred Hutchinson Cancer Center
Seattle, Washington
Newcastle Private Hospital
New Lambton Heights, New South Wales, Australia
Tasman Oncology Research
Southport, Queensland, Australia
Cancer Research SA
Adelaide, South Australia, Australia
Southern Oncology Clinical Research Unit
Bedford Park, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.